Zydus, ICMR to Conduct Phase III Desidustat Trial for Sickle Cell Anaemia
Zydus’ Desidustat received approval from the Drug Controller General of India (DCGI) in March 2022 for the treatment of anaemia in patients with chronic kidney disease (CKD).
E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Zydus’ Desidustat received approval from the Drug Controller General of India (DCGI) in March 2022 for the treatment of anaemia in patients with chronic kidney disease (CKD).
Zydus Lifesciences and Sunshine Healthcare have established a joint venture company to establish a pharma manufacturing facility in Sri Lanka.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.

